BiotechTube

Radiation: 131I-MIBG + Dinutuximab + Vorinostat

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroblastoma

Conditions

Neuroblastoma

Trial Timeline

Jul 31, 2026 → Jul 31, 2031

NCT ID
NCT07261241

About Radiation: 131I-MIBG + Dinutuximab + Vorinostat

Radiation: 131I-MIBG + Dinutuximab + Vorinostat is a phase 2 stage product being developed by United Therapeutics for Neuroblastoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07261241. Target conditions include Neuroblastoma.

What happened to similar drugs?

0 of 1 similar drugs in Neuroblastoma were approved

Approved (0) Terminated (0) Active (1)
🔄18F-MFBGIlluminaPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07261241Phase 2Recruiting

Competing Products

20 competing products in Neuroblastoma

See all competitors
ProductCompanyStageHype Score
LY3295668 Erbumine + Topotecan + CyclophosphamideEli LillyPhase 1
33
ZD6474 + Retinoic AcidAstraZenecaPhase 1
21
Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acidAstraZenecaPhase 2
35
PRRT with 177Lu-DOTATATENovartisPhase 1
36
Topotecan + Temozolomide + RibociclibNovartisPhase 1
21
Topotecan hydrochlorideNovartisPhase 2
35
Ribociclib + CeritinibNovartisPhase 1
21
Bevacizumab + Temozolomide + Temozolomide + Irinotecan + Bevacizumab + Topotecan + Temozolomide + Dinutuximab Beta + CyclophosphamideRochePhase 2
39
GPC2 CAR T cellsGilead SciencesPhase 1
36
lorlatinibPfizerPre-clinical
18
Lorlatinib + Cyclophosphamide + Topotecan + Filgrastim/pegfilgrastimPfizerPhase 1
29
Nifurtimox + Cyclophosphamide + TopotecanBayerPhase 2
32
DinutuximabUnited TherapeuticsPre-clinical
15
Dinutuximab with ChemotherapyUnited TherapeuticsPhase 1
30
ch14.18 -NCI + ch14.18-UTC + Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) + Aldesleukin (IL-2) + IsotretinoinUnited TherapeuticsPhase 1/2
29
Dinutuximab + Irinotecan Hydrochloride + Sargramostim + Temozolomide + TemsirolimusUnited TherapeuticsPhase 2
32
Dinutuximab + NK Cells + LenalidomideUnited TherapeuticsPhase 1
30
MAb-3F8 + Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) + 13-cis-Retinoic AcidUnited TherapeuticsPhase 2
24
Dinutuximab + Vorinostat + Sargramostim + Potassium IodideUnited TherapeuticsPhase 1
26
Universal Donor (UD) TGFβi NK Cells + Temozolomide + Irinotecan + Dinutuximab + GM-CSFUnited TherapeuticsPhase 2
39